{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T10:11:38Z","timestamp":1774779098137,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008021","name":"Bristol Myers Squibb","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008021","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["ejinme.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.ejim.2019.05.017","type":"journal-article","created":{"date-parts":[[2019,5,18]],"date-time":"2019-05-18T11:28:41Z","timestamp":1558178921000},"page":"57-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Body mass index as a driver of selection of biologic therapy in rheumatoid arthritis. Results from the US-CLARA study"],"prefix":"10.1016","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0906-4647","authenticated-orcid":false,"given":"Marco","family":"Di Carlo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fausto","family":"Salaffi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Gremese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Lapadula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianfranco","family":"Ferraccioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2019.05.017_bb0005","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13013","article-title":"Influence of baseline modified rheumatic disease comorbidity index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with rheumatoid arthritis, Spondyloarthritis, and psoriatic arthritis in real-world settings","volume":"48","author":"Iannone","year":"2018","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.ejim.2019.05.017_bb0010","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1136\/annrheumdis-2013-205094","article-title":"Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis","volume":"73","author":"Sandberg","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2019.05.017_bb0015","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.autrev.2016.01.010","article-title":"Impact of obesity on the clinical outcome of rheumatologic patients in biotherapy","volume":"15","author":"Iannone","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ejim.2019.05.017_bb0020","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/1759720X18783894","article-title":"Inflammation, obesity and rheumatic disease: common mechanistic links. A narrative review","volume":"10","author":"Nikiphorou","year":"2018","journal-title":"Ther Adv Musculoskel Dis"},{"key":"10.1016\/j.ejim.2019.05.017_bb0025","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/art.30136","article-title":"Bodymass index and clinical response to infliximab in rheumatoid arthritis","volume":"63","author":"Klaasen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejim.2019.05.017_bb0030","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/acr.21768","article-title":"Obesity and reduction of the response rate to anti-tumor necrosis factor \u03b1 in rheumatoid arthritis: an approach to a personalized medicine","volume":"65","author":"Gremese","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.ejim.2019.05.017_bb0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195123","article-title":"Obesity and response to anti-tumor necrosis factor-\u03b1 agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis","volume":"13","author":"Singh","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ejim.2019.05.017_bb0040","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1007\/s10067-017-3788-1","article-title":"Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis","volume":"36","author":"D'Agostino","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ejim.2019.05.017_bb0045","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.semarthrit.2017.09.013","article-title":"The UltraSound-CLinical ARthritis activity (US-CLARA) index: properties of a new composite disease activity index for rheumatoid arthritis","volume":"47","author":"Salaffi","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ejim.2019.05.017_bb0050","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European league against rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejim.2019.05.017_bb0055","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/acr.22763","article-title":"Patient-reported outcomes from a two-year head-to-head comparison of subcutaneous Abatacept and Adalimumab for rheumatoid arthritis","volume":"68","author":"Fleischmann","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.ejim.2019.05.017_bb0060","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1136\/annrheumdis-2013-203843","article-title":"Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial","volume":"73","author":"Schiff","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2019.05.017_bb0065","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2014-206106","article-title":"Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period","volume":"74","author":"Emery","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2019.05.017_bb0070","first-page":"2485","article-title":"Musculoskeletal ultrasound including definitions for ultrasonographic pathology","volume":"32","author":"Wakefield","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ejim.2019.05.017_bb0075","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/art.1780300603","article-title":"Articular indices of joint inflammation in rheumatoid arthritis. Correlation with the acute-phase response","volume":"30","author":"Thompson","year":"1987","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejim.2019.05.017_bb0080","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/art.1780380612","article-title":"A self-administered rheumatoid arthritis disease activity index (RADAI) for epidemiologic research. Psychometric properties and correlation with parameters of disease activity","volume":"38","author":"Stucki","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejim.2019.05.017_bb0085","first-page":"186","article-title":"Psychometric properties of an index of three patient reported outcome (PRO) measures, termed the CLinical ARthritis activity (PRO-CLARA) in patients with rheumatoid arthritis. The NEW INDICES study","volume":"28","author":"Salaffi","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ejim.2019.05.017_bb0090","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10067-012-2101-6","article-title":"\u201cNEW INDICES\u201d study group. Classical test theory and Rasch analysis validation of the recent-onset arthritis disability questionnaire in rheumatoid arthritis patients","volume":"32","author":"Salaffi","year":"2013","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ejim.2019.05.017_bb0095","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/930756","article-title":"Patient acceptable symptom state in self-report questionnaires and composite clinical disease index for assessing rheumatoid arthritis activity: identification of cut-off points for routine care","volume":"2015","author":"Salaffi","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.ejim.2019.05.017_bb0100","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejim.2019.05.017_bb0105","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/art.30129","article-title":"American College of Rheumatology\/European league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials","volume":"63","author":"Felson","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejim.2019.05.017_bb0110","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/ar4565","article-title":"Moving towards personalized medicine in rheumatoid arthritis","volume":"16","author":"de Jong","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ejim.2019.05.017_bb0115","article-title":"Predictors of treatment response in rheumatoid arthritis","author":"Lequerr\u00e9","year":"2018","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.ejim.2019.05.017_bb0120","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/COH.0b013e32833ed177","article-title":"What are biomarkers?","volume":"5","author":"Strimbu","year":"2010","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.ejim.2019.05.017_bb0125","doi-asserted-by":"crossref","first-page":"576","DOI":"10.3389\/fimmu.2014.00576","article-title":"Obesity as a risk and severity factor in rheumatic diseases (autoimmune chronic inflammatory diseases)","volume":"5","author":"Gremese","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejim.2019.05.017_bb0130","doi-asserted-by":"crossref","first-page":"212","DOI":"10.23736\/S0026-4806.17.05022-4","article-title":"Obesity and cardiovascular diseases","volume":"108","author":"Kachur","year":"2017","journal-title":"Minerva Med"},{"key":"10.1016\/j.ejim.2019.05.017_bb0135","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1136\/annrheumdis-2017-211569","article-title":"Obesity and rates of clinical remission and low MRI inflammation in rheumatoid arthritis","volume":"76","author":"George","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2019.05.017_bb0140","doi-asserted-by":"crossref","first-page":"580","DOI":"10.3899\/jrheum.140673","article-title":"Response to tocilizumab in rheumatoid arthritis is not influenced by the body mass index of the patient","volume":"42","author":"Pers","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ejim.2019.05.017_bb0145","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s10067-016-3183-3","article-title":"Body mass index and response to tocilizumab in rheumatoid arthritis: a real life study","volume":"35","author":"Gardette","year":"2016","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ejim.2019.05.017_bb0150","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jbspin.2015.02.011","article-title":"Body mass index and response to rituximab in rheumatoid arthritis","volume":"82","author":"Ottaviani","year":"2015","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.ejim.2019.05.017_bb0155","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s10067-016-3505-5","article-title":"Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the pan-European registry collaboration for abatacept (PANABA)","volume":"36","author":"Iannone","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ejim.2019.05.017_bb0160","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1136\/annrheumdis-2015-207709","article-title":"Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the APPRAISE study","volume":"75","author":"D'Agostino","year":"2016","journal-title":"Ann Rheum Dis"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095362051930175X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095362051930175X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,18]],"date-time":"2022-09-18T07:19:21Z","timestamp":1663485561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095362051930175X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":32,"alternative-id":["S095362051930175X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2019.05.017","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Body mass index as a driver of selection of biologic therapy in rheumatoid arthritis. Results from the US-CLARA study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2019.05.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}